FDA Rejects Over 88,000 Nicotine Products, Crackdown Continues

Aug.05.2022
FDA Rejects Over 88,000 Nicotine Products, Crackdown Continues
FDA rejects manufacturers of over 88,000 nicotine-containing products, including synthetic nicotine, without approval. Evaluation of over 350 products ongoing.

The FDA announced on Wednesday that they have sent "refuse to accept" letters to manufacturers of over 88,000 products containing laboratory-made nicotine.


Stephanie Keith/Getty Images (no translation needed as this is already in standard journalistic English)


Brian Kin, Director of the Center for Tobacco Products, revealed the progress of the FDA's regulation of non-tobacco nicotine sources (i.e. synthetic nicotine). The FDA was authorized earlier this year to regulate synthetic nicotine.


Regulatory gray area.


Brian King stated in a letter to unapproved makers of nasal snuff that "selling or distributing any new tobacco products without pre-market authorization in the U.S. market is illegal." The FDA has not approved any synthetic nicotine products for marketing.


According to regulations set by the FDA, as of July 13th, all unauthorized synthetic nicotine products are considered illegal. Therefore, technically, any manufacturer that has not received FDA approval cannot sell their products after that date.


However, the FDA also noted that it will continue to evaluate over 350 synthetic nicotine products. While many of these products (most of which are e-cigarettes) are technically not allowed to be sold, it is still unclear whether the FDA will remove them from the market upon evaluation. The FDA has exercised enforcement discretion for e-cigarettes containing tobacco-derived nicotine, allowing them to remain on shelves while continuing to weigh their sale.


A buildup process


Jonathan Foulds, a public health science professor specializing in tobacco addiction at Penn State College of Medicine, told Pulse that some manufacturers of synthetic nicotine electronic cigarettes are undoubtedly bad. They exploit regulatory loopholes to stay on the market, with their products mainly targeting teenagers.


Given the tight timeline for compiling evidence, other manufacturers may not have had the opportunity to submit applications to the FDA. "To be honest, I'd be surprised if any of them got authorization," he told Pulse. "It's a lot of work that requires a great deal of information and proper research, which simply can't be completed in just two months." He noted that even electronic cigarette manufacturers that use tobacco-derived nicotine have been unable to meet the FDA's evidence standards, despite having had years to apply for marketing orders.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the content. The purpose of translating this article is solely for industry discussions and research.


Due to limitations in translation ability, the translated article may not fully convey the intended meaning of the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions or positions.


The compilation of information belongs to the original media and author, and in the event of copyright infringement, please contact us for deletion.


He added, "If they are to withdraw from the market during the review by the agency, it would be fine by me, but they should have enough time to tidy up their applications.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Four CrossBar 20K disposable e-cigarettes appeared on Pennsylvania's 163-entry ENDS directory ahead of enforcement beginning October 19, 2026. The devices feature 13mL e-liquid reservoirs, 50mg/mL nicotine, 2,000mAh batteries and 0.9Ω mesh coils, with advertised puff counts of up to 20,000. CrossBar was the only modern high-puff disposable series among the directory's 15 disposable entries. Its packaging emphasizes New York design and Japanese-origin flavoring, while historical CrossBar records identify a registered U.S. tobacco manufacturing-related establishment. The link between the newer 13mL devices and earlier 1.3mL PMTA filings remains unconfirmed.
product
Oct.26
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City's Department of Consumer and Worker Protection (DCWP) opened applications on November 2, 2026, for a lottery covering tobacco and electronic cigarette retail dealer licenses, with a deadline of 5 p.m. New York local time on November 30. According to the city's October 1 notice, 55 electronic cigarette retail license slots are available across 23 community districts, including 28 in Brooklyn, alongside 322 tobacco retail license slots across 41 districts. Businesses must enter the lottery and, if invited, complete licensing requirements within 65 days. New York City continues to restrict e-cigarette retail sales to tobacco-flavored or unflavored products, while city retail licenses do not replace FDA product marketing authorization.
Market
Nov.04
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23